𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Induction of B cell activities by interleukin 4 is inhibited by a receptor-specific monoclonal antibody in vitro

✍ Scribed by Charles R. Maliszewski; Timothy A. Sato; Tim Vanden Bos; M. Patricia Beckmann; Kenneth H. Grabstein


Publisher
John Wiley and Sons
Year
1990
Tongue
English
Weight
558 KB
Volume
20
Category
Article
ISSN
0014-2980

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Inhibition and enhancement of in vitro h
✍ Richard G. Titus; Giampietro Corradin πŸ“‚ Article πŸ“… 1986 πŸ› John Wiley and Sons 🌐 English βš– 516 KB

A murine monoclonal antibody (mAb) specific for apocytochrome c was found to be able to either inhibit or enhance the helper activity of mouse apocytochrome c- specific T cell clones and populations in a hapten (trinitropheny1)-carrier (apocytochrome c) system of T-B cell cooperation. This effect of

In vitro cytotoxicity following specific
✍ Konstantinos N. Syrigos; Gail Rowlinson-Busza; Agamemnon A. Epenetos πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 French βš– 111 KB πŸ‘ 1 views

We describe a novel version of antibody-directed enzyme prodrug therapy (ADEPT), with the use of amygdalin as prodrug. Amygdalin is a naturally occurring cyanogenic glycoside, which can be cleaved by sweet almond ␀-glucosidase to yield free cyanide. If amygdalin could be activated specifically at th

Shedding of the soluble form of CD30 fro
✍ Ottmar Horn-Lohrens; Markus Tiemann; Hans Lange; JΓΆrg Kobarg; Martin Hafner; Hin πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 French βš– 719 KB

## Abstract The CD30‐activation marker was detected as the Hodgkin‐associated Ki‐I antigen and is regarded as a target for the treatment of Hodgkin patients with immunotoxins. The CD30 is released from tumor cells and this soluble CD30 (sCD30) is an indicator of the disease activity. Since the shed